In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection.
We tested the in vitro activity of oritavancin against 185 staphylococci associated with prosthetic joint infection, including 37 methicillin-resistant S. aureus, 67 methicillin-susceptible S. aureus, 59 methicillin-resistant S. epidermidis (MRSE), and 22 methicillin-susceptible S. epidermidis (MSSE) isolates. The oritavancin MIC50 for S. aureus and MSSE was 0.03 μg/mL, and for MRSE, it was 0.06 μg/mL; MIC90 for S. aureus and S. epidermidis was 0.12 μg/mL for both the methicillin-resistant and -susceptible subgroups. The oritavancin MBBC50 for S. aureus and S. epidermidis was 2 μg/mL for both the methicillin-resistant and -susceptible subgroups; the MBBC90 for S. aureus and MSSE was 4 μg/mL, and for MRSE, it was 8 μg/mL.